JP2016539925A5 - - Google Patents

Download PDF

Info

Publication number
JP2016539925A5
JP2016539925A5 JP2016525584A JP2016525584A JP2016539925A5 JP 2016539925 A5 JP2016539925 A5 JP 2016539925A5 JP 2016525584 A JP2016525584 A JP 2016525584A JP 2016525584 A JP2016525584 A JP 2016525584A JP 2016539925 A5 JP2016539925 A5 JP 2016539925A5
Authority
JP
Japan
Prior art keywords
composition
citrullinated
disorder
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016525584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539925A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/072606 external-priority patent/WO2015059168A1/en
Publication of JP2016539925A publication Critical patent/JP2016539925A/ja
Publication of JP2016539925A5 publication Critical patent/JP2016539925A5/ja
Pending legal-status Critical Current

Links

JP2016525584A 2013-10-22 2014-10-22 Tlr4リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 Pending JP2016539925A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361894042P 2013-10-22 2013-10-22
US61/894,042 2013-10-22
PCT/EP2014/072606 WO2015059168A1 (en) 2013-10-22 2014-10-22 Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018246722A Division JP2019048895A (ja) 2013-10-22 2018-12-28 Tlr4リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物

Publications (2)

Publication Number Publication Date
JP2016539925A JP2016539925A (ja) 2016-12-22
JP2016539925A5 true JP2016539925A5 (https=) 2017-11-30

Family

ID=51866128

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016525584A Pending JP2016539925A (ja) 2013-10-22 2014-10-22 Tlr4リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物
JP2018246722A Withdrawn JP2019048895A (ja) 2013-10-22 2018-12-28 Tlr4リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物
JP2020177986A Pending JP2021006592A (ja) 2013-10-22 2020-10-23 Tlr4リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018246722A Withdrawn JP2019048895A (ja) 2013-10-22 2018-12-28 Tlr4リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物
JP2020177986A Pending JP2021006592A (ja) 2013-10-22 2020-10-23 Tlr4リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物

Country Status (7)

Country Link
US (2) US9688769B2 (https=)
EP (1) EP3060250A1 (https=)
JP (3) JP2016539925A (https=)
CN (1) CN105899231A (https=)
AU (2) AU2014338991B2 (https=)
CA (1) CA2928317A1 (https=)
WO (1) WO2015059168A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037613T2 (hu) * 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
WO2015059168A1 (en) 2013-10-22 2015-04-30 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
US20170038381A1 (en) * 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
CN110073217A (zh) 2016-10-04 2019-07-30 豪夫迈·罗氏有限公司 用于鉴定合成分类器的系统和方法
RU2757771C2 (ru) * 2017-02-07 2021-10-21 Люфстоун Ас Биомаркеры для диагностики связанного с имплантом риска повторной операции с имплантом из-за асептического расшатывания
WO2020225549A1 (en) * 2019-05-06 2020-11-12 The Francis Crick Institute Limited Method for preventing inflammation
WO2021119761A1 (en) * 2019-12-20 2021-06-24 Hudson Institute of Medical Research Cxcl10 binding proteins and uses thereof
CA3174429A1 (en) * 2020-04-20 2021-10-28 Edesa Biotech Research Inc. Compositions and methods for treatment of acute respiratory distress syndrome
CN113358872B (zh) * 2021-06-03 2022-10-21 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 用于评估肿瘤免疫治疗疗效的标志物组及系统

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7674884B2 (en) 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
ES2382039T3 (es) * 2003-12-10 2012-06-04 Novimmune Sa Anticuerpos anti-TLR4/MD-2 neutralizantes y métodos de uso de los mismos
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
ES2388501T3 (es) 2004-08-12 2012-10-16 Helsinn Healthcare S.A. Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal
PT1830881E (pt) * 2004-12-10 2010-08-30 Novimmune Sa Terapias de combinação visando múltiplos receptores do tipo toll e a sua utilização
CN101248105B (zh) * 2005-08-25 2012-10-10 克雷毕里斯治疗股份公司 K-252a及其衍生物的聚合物缀合物
WO2007022999A1 (en) 2005-08-25 2007-03-01 Creabilis Therapeutics S.P.A. Polymer conjugates of k-252a and derivatives thereof
US20070148704A1 (en) * 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
US7712333B2 (en) 2006-03-29 2010-05-11 Asahi Glass Company, Limited Method for smoothing a surface of a glass substrate for a reflective mask blank used in EUV lithography
JP2010526868A (ja) 2007-05-14 2010-08-05 ノビミューン エスアー 改変されたエフェクター機能を有するFc受容体結合ポリペプチド
CN101589491B (zh) 2007-07-24 2011-07-27 松下电器产业株式会社 镍氢电池用负极材料及其处理方法以及镍氢电池
WO2009138494A2 (en) 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
US9140701B2 (en) * 2009-08-18 2015-09-22 The Board Of Trustees Of The Leland Stanford Junior University Fibrinogen immune complexes to diagnose and guide therapy in rheumatoid arthritis
BR112013011176A2 (pt) * 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
US8734790B2 (en) * 2011-01-10 2014-05-27 Novimmune Sa Anti-TLR4 antibodies and methods of use thereof
US20140378531A1 (en) * 2012-02-01 2014-12-25 New York University Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
US20160159922A1 (en) 2013-07-24 2016-06-09 Vilara Ab Novel Antibodies for the Diagnosis and Treatment of Rheumatoid Arthritis
WO2015059168A1 (en) 2013-10-22 2015-04-30 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers

Similar Documents

Publication Publication Date Title
JP2016539925A5 (https=)
Titcombe et al. Pathogenic citrulline‐multispecific B cell receptor clades in rheumatoid arthritis
JP2019048895A5 (https=)
ES2989669T3 (es) Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana
Vaisman-Mentesh et al. Molecular landscape of anti-drug antibodies reveals the mechanism of the immune response following treatment with TNFα antagonists
RU2017107773A (ru) Антитела, специфичные к ммр9
Chemin et al. A novel HLA–DRB1* 10: 01–restricted T cell epitope from citrullinated type II collagen relevant to rheumatoid arthritis
Charles et al. Somatic hypermutations confer rheumatoid factor activity in hepatitis C virus–associated mixed cryoglobulinemia
JP2015533788A5 (https=)
Goh et al. A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy
JP2012012402A5 (https=)
Von Büdingen et al. Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce “oligoclonal bands”
JP2012143232A5 (https=)
Clemente et al. Role of anti-osteopontin antibodies in multiple sclerosis and experimental autoimmune encephalomyelitis
Pelzek et al. Persistence of Disease‐Associated Anti–Citrullinated Protein Antibody–Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission
JP2021500916A5 (https=)
JP2014518883A5 (https=)
JP2013531655A5 (https=)
HK1219512A1 (zh) 用於诊断和治疗炎性肠病的方法
EP3463482A1 (en) Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions
JP2018507254A5 (https=)
JP2024502091A5 (https=)
Maurer et al. Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination
WO2017218677A3 (en) Identification and medical applications of anti-citrullinated-protein antibodies in rheumatoid arthritis
RU2017132168A (ru) Антитела, нацеленные на о-антиген на основе галактана из к.pneumoniae